Agios Pharmaceuticals Inc (AGIO) : Ghost Tree Capital added new position in Agios Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 140,000 shares of Agios Pharmaceuticals Inc which is valued at $6.6 Million , the company said in a statement filed on May 13, 2016 with the SEC.Agios Pharmaceuticals Inc makes up approximately 5.28% of Ghost Tree Capital’s portfolio.
Other Hedge Funds, Including , Laurion Capital Management Lp added AGIO to its portfolio by purchasing 30,000 company shares during the most recent quarter which is valued at $1.4 Million. Agios Pharmaceuticals Inc makes up approx 0.13% of Laurion Capital Management Lp’s portfolio.Blackrock Fund Advisors boosted its stake in AGIO in the latest quarter, The investment management firm added 46,287 additional shares and now holds a total of 730,197 shares of Agios Pharmaceuticals Inc which is valued at $34.2 Million. Agios Pharmaceuticals Inc makes up approx 0.01% of Blackrock Fund Advisors’s portfolio.Proshare Advisors reduced its stake in AGIO by selling 2,673 shares or 8.55% in the most recent quarter. The Hedge Fund company now holds 28,585 shares of AGIO which is valued at $1.2 Million. Agios Pharmaceuticals Inc makes up approx 0.02% of Proshare Advisors’s portfolio. Nisa Investment Advisors L.l.c. added AGIO to its portfolio by purchasing 200 company shares during the most recent quarter which is valued at $9,790.
Agios Pharmaceuticals Inc opened for trading at $48.72 and hit $52.71 on the upside on Wednesday, eventually ending the session at $52.63, with a gain of 8.87% or 4.29 points. The heightened volatility saw the trading volume jump to 10,62,452 shares. Company has a market cap of $1,996 M.
On the company’s financial health, Agios Pharmaceuticals Inc reported $-0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.93. The company had revenue of $31.28 million for the quarter, compared to analysts expectations of $25.66 million. The company’s revenue was down -8.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.13 EPS.
Many Wall Street Analysts have commented on Agios Pharmaceuticals Inc. Company shares were Reiterated by SunTrust on May 18, 2016 to “Buy”, Firm has raised the Price Target to $ 65 from a previous price target of $57 .Company shares were Reiterated by Sun Trust Rbsn Humphrey on May 18, 2016 to “Buy”, Firm has raised the Price Target to $ 65 from a previous price target of $57 .Sun Trust Rbsn Humphrey Initiated Agios Pharmaceuticals Inc on Mar 30, 2016 to “Buy”, Price Target of the shares are set at $57.
Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.